The REG1 anticoagulation system

A novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome

John Paul Vavalle, Mauricio G Cohen

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Antithrombotic agents including anticoagulants and antiplatelets are the cornerstone of treatment of acute coronary syndromes. Currently available anticoagulants have several important limitations including unpredictable pharmacodynamics, immunogenicity, and difficulty in reversibility. A potent anticoagulant that has predictable efficacy, is easily reversible should the clinical need arise, and reduces ischemic events without an increase in bleeding risk would overcome many of the current limitations. Inhibition of factor IX in the coagulation cascade has shown promise as a target for development of a novel anticoagulant with a favorable bleeding risk. Aptamers are small oligonucleotides that can be developed to inhibit specific protein targets with high affinity and used as active drugs. Because aptamers are made of oligonucleotide sequences, they provide the code for their own complement (reversal agent) that can be developed and used to inhibit their function. The REG1 anticoagulation system is a novel, aptamer-based, factor IXa inhibitor that is being developed for use in patients undergoing percutaneous coronary intervention and the treatment of acute coronary syndrome.

Original languageEnglish
Pages (from-to)371-382
Number of pages12
JournalFuture Cardiology
Volume8
Issue number3
DOIs
StatePublished - May 1 2012

Fingerprint

Nucleotide Aptamers
Factor IX
Acute Coronary Syndrome
Anticoagulants
Technology
Oligonucleotides
Factor IXa
Hemorrhage
Fibrinolytic Agents
Percutaneous Coronary Intervention
Therapeutics
Pharmaceutical Preparations
Proteins

Keywords

  • anivamersen
  • antidotecontrolled anticoagulation
  • aptamer
  • factor IX
  • pegnivacogin
  • REG1 anticoagulation system

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Molecular Medicine

Cite this

@article{c20cbe9c35394646905cb2c0efb6fc83,
title = "The REG1 anticoagulation system: A novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome",
abstract = "Antithrombotic agents including anticoagulants and antiplatelets are the cornerstone of treatment of acute coronary syndromes. Currently available anticoagulants have several important limitations including unpredictable pharmacodynamics, immunogenicity, and difficulty in reversibility. A potent anticoagulant that has predictable efficacy, is easily reversible should the clinical need arise, and reduces ischemic events without an increase in bleeding risk would overcome many of the current limitations. Inhibition of factor IX in the coagulation cascade has shown promise as a target for development of a novel anticoagulant with a favorable bleeding risk. Aptamers are small oligonucleotides that can be developed to inhibit specific protein targets with high affinity and used as active drugs. Because aptamers are made of oligonucleotide sequences, they provide the code for their own complement (reversal agent) that can be developed and used to inhibit their function. The REG1 anticoagulation system is a novel, aptamer-based, factor IXa inhibitor that is being developed for use in patients undergoing percutaneous coronary intervention and the treatment of acute coronary syndrome.",
keywords = "anivamersen, antidotecontrolled anticoagulation, aptamer, factor IX, pegnivacogin, REG1 anticoagulation system",
author = "Vavalle, {John Paul} and Cohen, {Mauricio G}",
year = "2012",
month = "5",
day = "1",
doi = "10.2217/fca.12.5",
language = "English",
volume = "8",
pages = "371--382",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - The REG1 anticoagulation system

T2 - A novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome

AU - Vavalle, John Paul

AU - Cohen, Mauricio G

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Antithrombotic agents including anticoagulants and antiplatelets are the cornerstone of treatment of acute coronary syndromes. Currently available anticoagulants have several important limitations including unpredictable pharmacodynamics, immunogenicity, and difficulty in reversibility. A potent anticoagulant that has predictable efficacy, is easily reversible should the clinical need arise, and reduces ischemic events without an increase in bleeding risk would overcome many of the current limitations. Inhibition of factor IX in the coagulation cascade has shown promise as a target for development of a novel anticoagulant with a favorable bleeding risk. Aptamers are small oligonucleotides that can be developed to inhibit specific protein targets with high affinity and used as active drugs. Because aptamers are made of oligonucleotide sequences, they provide the code for their own complement (reversal agent) that can be developed and used to inhibit their function. The REG1 anticoagulation system is a novel, aptamer-based, factor IXa inhibitor that is being developed for use in patients undergoing percutaneous coronary intervention and the treatment of acute coronary syndrome.

AB - Antithrombotic agents including anticoagulants and antiplatelets are the cornerstone of treatment of acute coronary syndromes. Currently available anticoagulants have several important limitations including unpredictable pharmacodynamics, immunogenicity, and difficulty in reversibility. A potent anticoagulant that has predictable efficacy, is easily reversible should the clinical need arise, and reduces ischemic events without an increase in bleeding risk would overcome many of the current limitations. Inhibition of factor IX in the coagulation cascade has shown promise as a target for development of a novel anticoagulant with a favorable bleeding risk. Aptamers are small oligonucleotides that can be developed to inhibit specific protein targets with high affinity and used as active drugs. Because aptamers are made of oligonucleotide sequences, they provide the code for their own complement (reversal agent) that can be developed and used to inhibit their function. The REG1 anticoagulation system is a novel, aptamer-based, factor IXa inhibitor that is being developed for use in patients undergoing percutaneous coronary intervention and the treatment of acute coronary syndrome.

KW - anivamersen

KW - antidotecontrolled anticoagulation

KW - aptamer

KW - factor IX

KW - pegnivacogin

KW - REG1 anticoagulation system

UR - http://www.scopus.com/inward/record.url?scp=84861736559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861736559&partnerID=8YFLogxK

U2 - 10.2217/fca.12.5

DO - 10.2217/fca.12.5

M3 - Article

VL - 8

SP - 371

EP - 382

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 3

ER -